A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: Short- and long-term efficacy and safety results

2005 ◽  
Vol 52 (2) ◽  
pp. 563-572 ◽  
Author(s):  
Nicolino Ruperto ◽  
Irina Nikishina ◽  
Evgueni D. Pachanov ◽  
Ynessa Shachbazian ◽  
Anne Marie Prieur ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Juvenile Idiopathic Arthritis ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Term Efficacy ◽  
Double Blind Clinical Trial ◽  
Short And Long Term

Rituximab in Previously Treated Primary Immune Thrombocytopenia Patients: Evaluation of Short- and Long-Term Efficacy and Safety

2013 ◽  
Vol 132 (1) ◽  
pp. 24-29 ◽  
Author(s):  
Cristina Santoro ◽  
Francesca Biondo ◽  
Erminia Baldacci ◽  
Maria Stefania De Propris ◽  
Anna Guarini ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Primary Immune Thrombocytopenia ◽  
Previously Treated ◽  
Short And Long Term

Long-term efficacy and safety of zolpidem extended-release 12.5 mg, in old patients with chronic primary insomnia: a randomized, double-blind, placebo-controlled, parallel-group, multicenter study

2011 ◽  
Vol 26 (S2) ◽  
pp. 1567-1567
Author(s):  
J. Zarra ◽  
L. Schmidt
Keyword(s):  
Extended Release ◽  
Sleep Onset ◽  
Primary Insomnia ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Old Patients ◽  
Double Blind Placebo ◽  
Term Efficacy ◽  
Parallel Group

ObjectiveTo evaluate long-term efficacy and safety of zolpidem extended-release, in old patients for chronic primary insomnia.DesignMulticenter, randomized, double-blind, placebo-controlled, parallel-group.MethodPopulation: Outpatient with aged more of 65 years. Diagnosis: DSM-IV criteria for chronic primary insomnia; Treatment: Single-dose zolpidem extended-release 12.5 mg (n = 128) or placebo (n = 127), self-administered every night.ResultsPatient's Global Impression (PGI) and Clinical Global Impression-Improvement (CGI-I) were assessed every 4 weeks up to six month. Patient Morning Questionnaire (PMQ), recorded daily, assessed subjective sleep measures-sleep onset latency (SOL), total sleep time (TST), number of awakenings (NAW), wake time after sleep onset (WASO), and quality of sleep (QOS)-and next-day functioning. Zolpidem extended-release also was statistically significantly superior to placebo at every time point for PGI (Items 1–4) and CGI-I (P < 0.0001, rank score), TST, WASO, QOS (P < 0.0001), and SOL (P < or = 0.0014); NAW (Months 2–6; P < 0.0001). Sustained improvement (P < 0.0001, all time points) was observed in morning sleepiness and ability to concentrate (P = 0.0014, month 6) with zolpidem extended-release compared with placebo. Most frequent adverse events for zolpidem extended-release were headache, anxiety and somnolence to the morning. No rebound effect was observed during the first 3 nights of discontinuation.ConclusionsThese findings establish the efficacy of dosing of zolpidem extended-release 12.5 mg for up to 6 months. Treatment provided sustained and significant improvements in sleep onset and maintenance and also improved next-day concentration and morning sleepiness.

Sign in / Sign up

Export Citation Format

Share Document